E.I. Du Pont De Nemours & Co. v. Hem Research, Inc.

576 A.2d 635, 1989 Del. Ch. LEXIS 146, 1989 WL 211206
CourtCourt of Chancery of Delaware
DecidedNovember 6, 1989
DocketCiv. A. 10747
StatusPublished
Cited by8 cases

This text of 576 A.2d 635 (E.I. Du Pont De Nemours & Co. v. Hem Research, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
E.I. Du Pont De Nemours & Co. v. Hem Research, Inc., 576 A.2d 635, 1989 Del. Ch. LEXIS 146, 1989 WL 211206 (Del. Ct. App. 1989).

Opinion

OPINION

JACOBS, Vice Chancellor.

The plaintiff, E.I. duPont de Nemours and Company, a Delaware corporation (“DuPont”) has moved for a preliminary injunction restraining the defendant, HEM Research, Inc., a Maryland corporation (“HEM”), from paying a dividend, making other distributions, or otherwise dissipating its assets other than in the ordinary course of its business. This is the decision of the Court on that motion.

I.

In this action, DuPont seeks to undo its shareholder and contractual relationship with HEM. HEM is a research corporation that owns certain rights with respect to Ampligen, which is a pharmaceutical compound being tested and developed for possible treatment of human immunodeficiency virus (“HIV”). In its amended complaint, DuPont alleges that HEM misrepresented the efficacy of Ampligen and thereby induced DuPont to execute a series of agreements with HEM relating to the research and commercial development of Ampligen. DuPont claims that it was also induced to invest over $30 million in HEM and Ampli-gen, of which $21 million was paid to HEM.

In this action DuPont seeks two forms of relief: (a) rescission of its agreements with HEM, including a money judgment to recover over $30 million in rescissory damages, and (b) an injunction preventing HEM from dissipating its assets other than in the ordinary course of business pending the determination of its rescission claim. DuPont contends that without an injunction it will suffer irreparable harm because (i) HEM’s net worth is presently insufficient to satisfy a possible money judgment in favor of DuPont, and (ii) HEM intends to declare a dividend and make other payments that would further frustrate its ability to collect such a judgment.

*637 In response to the amended complaint, HEM moved to dismiss this action in its entirety for lack of subject matter jurisdiction and for failure to state a claim upon which relief may be granted. In a Memorandum Opinion dated October 13, 1989, Chancellor Allen granted HEM’s motion as to the rescission claim on jurisdictional grounds. The Court held that DuPont was really seeking money damages for which rescission at law was an adequate legal remedy; however, the Chancellor reserved decision on the question of whether equitable jurisdiction had been conferred by virtue of DuPont’s request for interim in-junctive relief. That issue had not been fully briefed and its determination would await the instant motion. E.I. duPont de Nemours v. HEM Research, Inc., Del.Ch., C.A. No. 10747, Allen, C., 1989 WL 122053 (October 13, 1989).

Thereafter, the parties engaged in discovery and filed briefs and affidavits on an expedited schedule. Oral argument on DuPont’s injunction motion took place on October 31, 1989.

II.

To obtain preliminary injunctive relief, the plaintiff must demonstrate that (a) it has a reasonable likelihood of success on the merits, (b) the failure to grant preliminary injunctive relief will cause it irreparable injury, and (c) the threatened injury to the plaintiff if relief is denied outweighs the threatened injury to the defendant if relief is granted. Ivanhoe Partners v. Newmont Mining Corp., Del.Supr., 535 A.2d 1334, 1341 (1987); Shields v. Shields, Del.Ch., 498 A.2d 161, 166 (1985).

In an effort to establish probable success on the merits, DuPont presented evidence designed to show that HEM had misrepresented the virtues of Ampligen, thereby inducing DuPont to enter into agreements with, and invest substantial monies in, HEM. Those incorrect statements are claimed to have been made in a draft article supplied by HEM to DuPont, which was later published in Lancet, a British medical journal, in June, 1987. The Lancet article discussed the efficacy and safety of Ampli-gen based upon an ongoing clinical study involving 10 patients infected with HIV. That article reported that the Ampligen treatment had had dramatic virological, immunological, and clinical effects on those patients, and it represented that Ampligen had a “profound and uniformly suppressive effect on HIV expression.”

DuPont contends that these representations about Ampligen’s efficacy did not accurately reflect the underlying clinical study data upon which the Lancet article was based, specifically, data derived from “co-culture” and “T4 Cell” testing. In fact, DuPont argues, that data demonstrated that the Ampligen treatment had no consistent effect upon the virus. It is undisputed that HEM formally warranted the truth of its representations made to DuPont in the Lancet article. DuPont contends that because those representations were inaccurate and were material inducements for it to enter into the various agreements with HEM, and to invest substantial funds in HEM and Ampligen, DuPont is entitled to rescission (including money damages).

HEM ardently disputes these contentions. It maintains that the representations in the Lancet article were factually correct and properly supported by the underlying data and that any errors in that article were minor and immaterial. Moreover, HEM argues, the Lancet article was but one part of a much larger body of Ampligen-related data that HEM supplied to DuPont and that DuPont does not dispute.

This thumbnail sketch of the parties’ factual positions does not, nor is it intended to, do justice to their detailed, elaborate, written and oral presentations on these questions. These conflicting “facts” involve intricate scientific laboratory data, and questions concerning the appropriate method for its evaluation, in a highly complex and specialized area. The parties’ presentations on these questions, supported by affidavits of respected medical and academic professionals from prestigious institutions, consumed the great bulk of the briefs submitted by both sides. But given the nar *638 row jurisdictional ground for this Court’s ruling, those scientific issues, though ably presented and clearly pertinent to the merits of the rescission claim, do not bear upon the question found here to be dispositive. Accordingly, the Court does not (because it need not) pronounce upon the probable merits of the parties’ factual claims concerning the accuracy of the Lancet article.

The facts relating to the payments that DuPont seeks to have enjoined are, however, pertinent. Those proposed payments, which total $1,154,000, are part of an earlier business transaction in which HEM settled certain litigation against it, and a new investor group acquired control of the company. As part of that transaction, HEM received over $1.45 million from the new investors and became obligated to make certain payments. Those payments include a dividend to HEM stockholders (including DuPont), and the reimbursement of a key HEM employee’s legal fees and lost compensation, of HEM’s former management’s severance benefits, and of the new investors’ legal fees.

On may 8, 1989, DuPont and HEM entered into an agreement pursuant to which HEM would refrain from making those payments for 180 days or until DuPont’s injunction claim was resolved, whichever came first.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Vama F.Z. Co. v. WS02, Inc.
Court of Chancery of Delaware, 2021
Eagle Force Holdings, LLC v. Campbell
187 A.3d 1209 (Supreme Court of Delaware, 2018)
DE RIVER AND BAY AUTH. v. York Hunter Const., Inc.
781 A.2d 1126 (New Jersey Superior Court App Division, 2001)
USH Ventures v. Global Telesystems Group, Inc.
796 A.2d 7 (Superior Court of Delaware, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
576 A.2d 635, 1989 Del. Ch. LEXIS 146, 1989 WL 211206, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ei-du-pont-de-nemours-co-v-hem-research-inc-delch-1989.